In Diabetics with Multivessel Disease SYNTAX Score Calculations Are Redundant

In diabetic patients with multivessel disease, anatomical complexity assessed by SYNTAX score is an independent predictor of combined events only por PCI patients, and has absolutely no consequence for surgery. The score should not be used to decide on a revascularization strategy. If the patient is diabetic and has multivessel disease, they simply ought to<a href="https://solaci.org/en/2019/01/04/in-diabetics-with-multivessel-disease-syntax-score-calculations-are-redundant/" title="Read more" >...</a>

Everolimus-Eluting Stents Finally Have a Rival and Not Just a “Non-Inferior” Stent

In this large randomized trial, there were significant differences as regards both target-lesion failure and target-vessel-related infarction, which persisted through a 2-year follow-up and favored treatment with an ultrathin-strut bioresorbable-polymer sirolimus-eluting stent (Orsiro) compared with the gold standard, a durable-polymer everolimus-eluting stent (Xience). Moreover, there were significantly lower rates of target lesion revascularization and late/very<a href="https://solaci.org/en/2019/01/04/everolimus-eluting-stents-finally-have-a-rival-and-not-just-a-non-inferior-stent/" title="Read more" >...</a>

Early Strut Coverage and Its Implications for Dual Antiplatelet Therapy

Optical coherence tomography (OCT)-guided drug-eluting stent implantation improves early strut coverage compared with angiography-guided angioplasty. No difference was observed in terms of strut coverage between permanent-polymer everolimus-eluting stents and bioresorbable-polymer biolimus-eluting stents. Short-term dual antiplatelet therapy may be feasible in selected patients with early strut coverage.   This study sought to measure early strut coverage<a href="https://solaci.org/en/2018/12/14/early-strut-coverage-and-its-implications-for-dual-antiplatelet-therapy/" title="Read more" >...</a>

SOLACI@SOVECI Symposium at the XVI Venezuelan Congress on Interventional Cardiology

The XVI Venezuelan Congress on Interventional Cardiology will take place next Saturday, December 1st, 2018, at La Trinidad Teaching Medical Center (Caracas). SOLACI is honored to contribute with the organization of this event by means of two symposiums addressing important issues related with Interventional Cardiology on Structural Heart Disease. Here is the detailed information for<a href="https://solaci.org/en/2018/11/27/solacisoveci-symposium-at-the-xvi-venezuelan-congress-on-interventional-cardiology/" title="Read more" >...</a>

La enfermedad coronaria funciona como un predictor a 30 días en el TAVI

CoreValve US Pivotal High Risk Trial: at 5 years, similar results

Courtesy of Dr. Carlos Fava. We are well aware of transcatheter aortic valve replacement’s (TAVR) effect in high-risk or inoperable patients at 5 years, even more after the PARTNER 1 trial. Yet, the outcomes of another relevant randomized study remained pending: el CoreValve US Pivotal High-Risk Trial. The CoreValve US Pivotal High-Risk Trial looked at the<a href="https://solaci.org/en/2018/11/21/corevalve-us-pivotal-high-risk-trial-at-5-years-similar-results/" title="Read more" >...</a>

Surprises in the Physiopathology of Critical Ischemia

Luminal thrombotic occlusions associated with non-significant atherosclerosis are commonly observed in patients with critical lower limb ischemia, which suggests the possibility of thromboembolic disease as a great contributor to ischemia. This was particularly verifiable in infrapopliteal vessels, thus showing a possible mechanism of progression from peripheral vascular disease to critical ischemia, as well as a<a href="https://solaci.org/en/2018/11/13/surprises-in-the-physiopathology-of-critical-ischemia/" title="Read more" >...</a>

TAVI en bajo riesgo con “cero” mortalidad y “cero” stroke

TAVR in Low-Risk Patients with “Zero” Mortality and “Zero” Stroke

Transcatheter aortic valve replacement (TAVR) is now the standard of care for patients with symptomatic severe aortic stenosis who are at extreme, high, or intermediate risk for surgery. This multicenter, prospective study (Feasibility of Transcatheter Aortic Valve Replacement in Low-Risk Patients With Symptomatic, Severe Aortic Stenosis) included low-risk patients and was approved by the United<a href="https://solaci.org/en/2018/11/09/tavr-in-low-risk-patients-with-zero-mortality-and-zero-stroke/" title="Read more" >...</a>

Practical Management of Coronary Perforations

Coronary perforation has an incidence of 0.5% and it is associated with a 13-fold increase in in-hospital events and a 5-fold increase in 30-day mortality. This event is so catastrophic that its management has become indispensable knowledge to all interventional cardiologists. This accident is most frequently provoked by artery over-dilation caused by a balloon or<a href="https://solaci.org/en/2018/11/06/practical-management-of-coronary-perforations/" title="Read more" >...</a>

Los 10 artículos más leídos de septiembre

The 10 most read articles of September

1- High-Sensitivity Troponins Turned All Events into Infarctions; the 4th Universal Definition Clarifies Things Myocardial infarction or myocardial injury? The Fourth Universal Definition of Myocardial Infarction (an update of the 2012 version) is here to clarify that not all cases of elevated cardiac troponin values are acute myocardial infarctions. Read more   2- A Simple<a href="https://solaci.org/en/2018/10/09/the-10-most-read-articles-of-september/" title="Read more" >...</a>

TCT 2018 | ABSORB IV: todavía le quedan vidas a las plataformas bioabsorbibles

TCT 2018 | ABSORB IV: Much Life Left for Bioresorbable Scaffolds

Previous studies have documented higher rates of adverse events with bioresorbable scaffolds (ABSORB) compared with metallic drug-eluting stents (DES). However, these studies included lesions smaller than recommended for these scaffolds and a suboptimal implantation technique. The ABSORB IV study, presented by Dr. Stone at TCT 2018 and published simultaneously in The Lancet, randomized patients to polymeric everolimus-eluting scaffold Absorb<a href="https://solaci.org/en/2018/10/08/tct-2018-absorb-iv-much-life-left-for-bioresorbable-scaffolds/" title="Read more" >...</a>

thrombosis